Influence of a 3-month letermovir treatment on gut permeability and inflammation in people living with HIV on antiretroviral therapy (EACS 2025) - Jul 16, 2025 - Abstract #eP183; Location: ePoster Exhibition; "Conclusions : Letermovir was safe and reduced anti-CMV IgG levels, but did not affect gut permeability or systemic inflammation in PWH on ART. Ongoing analyses are exploring whether letermovir's immunomodulatory effects influence HIV reservoir size and T cell clonal expansion in blood and gut biopsies."
Cytomegalovirus Infection • Human Immunodeficiency Virus • Infectious Disease • CD4 • CD8 • REG3A
|
|
S. Isnard 1,2; L. Royston 1,3; C.A Berini 1,2; T. Mabanga 1,2; J. Girouard 1,2; T. Bessissow 4; P.L Lakatos 4,5; C.T Costiniuk 1,2; B. Lebouché 1,2; J.-P. Routy 1,2,6; CTN PT047 CIAO study
|